[go: up one dir, main page]

CY1121466T1 - Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης - Google Patents

Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης

Info

Publication number
CY1121466T1
CY1121466T1 CY20181100623T CY181100623T CY1121466T1 CY 1121466 T1 CY1121466 T1 CY 1121466T1 CY 20181100623 T CY20181100623 T CY 20181100623T CY 181100623 T CY181100623 T CY 181100623T CY 1121466 T1 CY1121466 T1 CY 1121466T1
Authority
CY
Cyprus
Prior art keywords
kallidine
des
arg10
antibodies
disclosure
Prior art date
Application number
CY20181100623T
Other languages
English (en)
Inventor
Dorothea Kominos
Jie Zhang
Alla PRITSKER
Matthew Davison
Nicolas Baurin
Govindan Subramanian
Xin Chen
Han Li
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49261064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121466(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of CY1121466T1 publication Critical patent/CY1121466T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η αποκάλυψη παρέχει αντισώματα που δεσμεύονται ειδικά σε Καλλιδίνη ή des-Arg10-Καλλιδίνη. Η αποκάλυψη παρέχει επίσης φαρμακευτικές συνθέσεις, καθώς και νουκλεϊκά οξέα που κωδικοποιούν αντισώματα αντι-Καλλιδίνης ή des-Arg10-Καλλιδίνης, ανασυνδυασμένους φορείς έκφρασης και κύτταρα ξενιστές για την παρασκευή τέτοιων αντισωμάτων, ή θραυσμάτων αυτών. Μέθοδοι χρήσης αντισωμάτων της αποκάλυψης για τη διαμόρφωση της δραστικότητας Καλλιδίνης ή des-Arg10-Καλλιδίνης ή για την ανίχνευση της Καλλιδίνης ή des-Arg10-Καλλιδίνης ή, είτε in vitro είτε in vivo, παρέχονται επίσης από την αποκάλυψη. Η αποκάλυψη παρέχει περαιτέρω μεθόδους παρασκευής αντισωμάτων που δεσμεύονται ειδικά σε πεπτίδιο τύπου des-Argg-Βραδυκινίνης και des-Arg10-Καλλιδίνης.
CY20181100623T 2012-03-28 2018-06-14 Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης CY1121466T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616845P 2012-03-28 2012-03-28
FR1350953 2013-02-04
PCT/US2013/031836 WO2013148296A1 (en) 2012-03-28 2013-03-15 Antibodies to bradykinin b1 receptor ligands

Publications (1)

Publication Number Publication Date
CY1121466T1 true CY1121466T1 (el) 2020-05-29

Family

ID=49261064

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100623T CY1121466T1 (el) 2012-03-28 2018-06-14 Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης

Country Status (39)

Country Link
US (5) US9376494B2 (el)
EP (2) EP3246339B1 (el)
JP (4) JP6779012B2 (el)
KR (4) KR20220031728A (el)
CN (2) CN113773385A (el)
AR (1) AR090352A1 (el)
AU (2) AU2013240242B2 (el)
BR (1) BR112014024282A2 (el)
CA (1) CA2868353C (el)
CL (2) CL2014002590A1 (el)
CO (1) CO7111293A2 (el)
CR (1) CR20140440A (el)
CY (1) CY1121466T1 (el)
DK (2) DK3246339T3 (el)
DO (1) DOP2014000199A (el)
EA (1) EA201491784A1 (el)
ES (1) ES2673869T3 (el)
GT (1) GT201400192A (el)
HK (1) HK1206754A1 (el)
HR (1) HRP20180928T1 (el)
HU (1) HUE037720T2 (el)
IL (1) IL234830B (el)
LT (1) LT2831113T (el)
MA (1) MA37407B1 (el)
MX (2) MX361874B (el)
MY (2) MY166157A (el)
NZ (1) NZ631543A (el)
PE (1) PE20142170A1 (el)
PH (1) PH12014501970A1 (el)
PL (1) PL2831113T3 (el)
PT (1) PT2831113T (el)
RS (1) RS57413B1 (el)
SG (2) SG10201702396QA (el)
SI (1) SI2831113T1 (el)
TR (1) TR201808486T4 (el)
TW (1) TWI605060B (el)
UA (1) UA117097C2 (el)
UY (1) UY34682A (el)
WO (1) WO2013148296A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2831113T3 (pl) * 2012-03-28 2018-08-31 Sanofi Przeciwciała przeciwko ligandom receptora bradykininy B1
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
MX2018007493A (es) 2015-12-15 2018-09-18 Dyax Corp Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido.
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
AU2018266711B2 (en) * 2017-05-08 2025-02-06 Adimab, Llc Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use
TW201945026A (zh) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 結合erfe之抗體及使用方法
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
ATE158615T1 (de) 1990-03-20 1997-10-15 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
CA2095836C (en) 1990-11-09 1999-04-06 Stephen D. Gillies Cytokine immunoconjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
EP0918872B1 (en) 1996-08-02 2008-02-20 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
EP1141024B1 (en) 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
KR20040088572A (ko) 2002-03-01 2004-10-16 이뮤노메딕스, 인코오포레이티드 제거율 증강을 위한 양특이성 항체 점 돌연변이들
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
AU2003262650B2 (en) 2002-08-14 2009-10-29 Macrogenics, Inc. FcgammaRIIB-specific antibodies and methods of use thereof
JP4580340B2 (ja) 2002-09-27 2010-11-10 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体およびそれらの生成方法
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
EP1587540B1 (en) 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US20050249723A1 (en) 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
AU2005272993B2 (en) 2004-07-15 2010-02-11 Xencor, Inc. Optimized Fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
KR20080015854A (ko) * 2005-06-14 2008-02-20 사이토스 바이오테크놀로지 아게 항원 컨쥬게이트 및 그의 용도
US7833260B2 (en) 2006-07-20 2010-11-16 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
KR20090088891A (ko) * 2006-11-15 2009-08-20 메다렉스, 인코포레이티드 비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
US20110022149A1 (en) 2007-06-04 2011-01-27 Cox Brian J Methods and devices for treatment of vascular defects
AU2008267038B2 (en) * 2007-06-12 2014-08-07 Ac Immune S.A. Humanized antibodies to amyloid beta
BRPI0815983A2 (pt) 2007-08-29 2018-05-22 Sanofi Aventis anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
DK2224954T3 (en) * 2007-11-07 2014-03-03 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2420245A1 (en) * 2010-08-18 2012-02-22 Max-Delbrück-Centrum Für Molekulare Medizin Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth
PL2831113T3 (pl) * 2012-03-28 2018-08-31 Sanofi Przeciwciała przeciwko ligandom receptora bradykininy B1

Also Published As

Publication number Publication date
EP3246339B1 (en) 2019-10-09
LT2831113T (lt) 2018-06-25
UY34682A (es) 2013-10-31
CN104334578A (zh) 2015-02-04
CL2014002590A1 (es) 2015-01-16
PE20142170A1 (es) 2015-01-07
CA2868353A1 (en) 2013-10-03
MY166157A (en) 2018-06-06
PL2831113T3 (pl) 2018-08-31
MA37407B1 (fr) 2018-03-30
TWI605060B (zh) 2017-11-11
MX2014011688A (es) 2015-01-22
KR20200121370A (ko) 2020-10-23
US9376494B2 (en) 2016-06-28
KR20220031728A (ko) 2022-03-11
DK3246339T3 (da) 2020-01-27
AU2013240242B2 (en) 2018-02-08
JP2021166538A (ja) 2021-10-21
IL234830B (en) 2018-11-29
HRP20180928T1 (hr) 2018-07-27
PT2831113T (pt) 2018-06-20
CA2868353C (en) 2023-10-31
KR20190121861A (ko) 2019-10-28
CN113773385A (zh) 2021-12-10
DOP2014000199A (es) 2014-10-31
US20160368976A1 (en) 2016-12-22
US20230399388A1 (en) 2023-12-14
WO2013148296A1 (en) 2013-10-03
GT201400192A (es) 2015-07-29
NZ631543A (en) 2017-03-31
MX361874B (es) 2018-12-18
EP2831113B1 (en) 2018-03-14
JP7411609B2 (ja) 2024-01-11
EA201491784A1 (ru) 2015-02-27
EP3246339A1 (en) 2017-11-22
UA117097C2 (uk) 2018-06-25
SG11201405162YA (en) 2014-09-26
KR102367723B1 (ko) 2022-02-28
ES2673869T3 (es) 2018-06-26
HK1206754A1 (en) 2016-01-15
SG10201702396QA (en) 2017-04-27
AR090352A1 (es) 2014-11-05
CL2017003039A1 (es) 2018-03-16
RS57413B1 (sr) 2018-09-28
BR112014024282A2 (pt) 2017-08-08
CN104334578B (zh) 2021-10-08
CO7111293A2 (es) 2014-11-10
JP2024038036A (ja) 2024-03-19
DK2831113T3 (en) 2018-06-25
SI2831113T1 (en) 2018-08-31
MA37407A1 (fr) 2016-05-31
TW201343671A (zh) 2013-11-01
JP6912441B2 (ja) 2021-08-04
JP2019050822A (ja) 2019-04-04
TR201808486T4 (tr) 2018-07-23
JP6779012B2 (ja) 2020-11-04
JP2015513903A (ja) 2015-05-18
HUE037720T2 (hu) 2018-09-28
US10465002B2 (en) 2019-11-05
PH12014501970A1 (en) 2014-11-17
US20150050270A1 (en) 2015-02-19
CR20140440A (es) 2014-11-17
AU2018203081A1 (en) 2018-05-24
KR102166083B1 (ko) 2020-10-16
MY184037A (en) 2021-03-17
KR20150002679A (ko) 2015-01-07
US20180222967A1 (en) 2018-08-09
KR102035882B1 (ko) 2019-10-24
US9879079B2 (en) 2018-01-30
EP2831113A1 (en) 2015-02-04
US20200115441A1 (en) 2020-04-16
MX2018015914A (es) 2021-12-08
AU2013240242A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
CY1123435T1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1123739T1 (el) Αντισωματα anti-cd38
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1124050T1 (el) Πρωτεϊνες δεσμευσης αντιγονου προσδετη ανθρωπινης cd30
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201491644A1 (ru) Фармацевтические композиции
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX2015011830A (es) Metodos de fabricacion y sintesis de grupos de enlace de aminoacidos conjugados con compuestos usados para la obtencion de imagenes dirigida de los tumores.
EA201991409A3 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
UY32971A (es) Proteínas de unión al antígeno de la il-23 humana
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn